Evidence map›Paper›PMID 42274941›Full record

ArticleGeroScience2026

Amyloid and tau pathologies are drivers of white matter damage in aging and Alzheimer's disease.

Farooq Kamal, Mahsa Dadar

Abstract read
PubMed Publisher
In one paragraph

Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Farooq KamalDepartment of Psychiatry, McGill University, 1033 Pine Ave W, Montreal, QC, H3A 1A1, Canada. farooq.kamal@mail.mcgill.ca.ORCID http://orcid.org/0000-0001-5197-3062
Mahsa DadarDepartment of Psychiatry, McGill University, 1033 Pine Ave W, Montreal, QC, H3A 1A1, Canada. mahsa.dadar@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

White matter hyperintensities (WMHs) are increasingly recognized as neuroimaging biomarkers of cerebrovascular pathology in Alzheimer's disease (AD), yet their temporal relationship with amyloid and tau accumulation remains unclear. While previous studies suggest bidirectional associations between WMHs and AD pathology, regional associations between WMHs and AD pathology have yet to be examined. This study investigated the temporal and regional associations between PET measures of amyloid (Aβ) and tau pathology and WMH burden in older adults. Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) included 1,241 older adults with Aβ and 636 with tau for cross-sectional analyses. Longitudinal analyses included 613 participants for Aβ change and 980 for WMH change (Aβ group), and 92 for tau change and 342 for WMH change (tau group). Linear models were used to i) assess associations between baseline regional WMH and Aβ and tau pathology, and ii) examine whether baseline pathology in one measure was associated with change in the other measure over two years. Baseline analyses revealed significant bidirectional associations between WMH burden and both Aβ (t = 2.29-3.70, p < .05) and tau pathology (t = 2.01-2.56, p < .05). Longitudinal analyses showed that baseline Aβ levels were associated with future WMH progression in frontal and parietal regions and in anterior and posterior composite regions (t = 2.07-3.09, p < .04), while baseline tau was linked to WMH increases in parietal regions (t = 2.98, p < .03). However, baseline WMH burden was not associated with accumulation of Aβ or tau pathology in any region. These findings suggest that Aβ and tau pathology drive future WMH progression rather than the reverse, with distinct regional patterns for each pathology type.

Indexed as

AgingAlzheimer's diseaseAmyloidDementiaTauWhite matter hyperintensity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.